Allianz Asset Management’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
Allianz Asset Management's CSTL Position: Q3 2026 in Review
Allianz Asset Management reduced its Castle Biosciences (CSTL) stake by 66% in Q3 2026, selling an estimated $17.4M and leaving 302,341 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #860.
Allianz Asset Management first reported a position in CSTL in Q1 2020 and has held it in 10 quarters since. The position peaked at $24.2M in Q4 2025. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- Allianz Asset Management held 302,341 shares of Castle Biosciences worth $10.7M as of Q3 2026.
- Allianz Asset Management sold 576,917 Castle Biosciences shares in Q3 2026, an estimated $17.4M.
- Castle Biosciences made up 0.01% of Allianz Asset Management's portfolio in Q3 2026, its #860 holding.
- Allianz Asset Management first reported a position in Castle Biosciences in Q1 2020 and has held it in 10 quarters since.
- Allianz Asset Management's Castle Biosciences position peaked at $24.2M in Q4 2025.
- 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on Allianz Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.